# OnCo record brenetafusp (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/brenetafusp/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "brenetafusp" ;
  schema:name "Brenetafusp"@en ;
  schema:description "Brenetafusp is a soluble T-cell receptor bispecific, tebentafusp's successor, that recognises a PRAME peptide on HLA-A*02:01 and drags T cells onto the tumour. A phase 3 with nivolumab in first-line melanoma is enrolling, but only patients carrying HLA-A*02:01, about half of those of European ancestry, are eligible."@en ;
  schema:url <https://onco.cc/drugs/brenetafusp/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://www.globenewswire.com/news-release/2026/05/31/3303917/0/en/immunocore-presents-updated-phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma.html> ;
  onco:status "phase-3" ;
  onco:modality "ImmTAC (PRAME TCR × CD3 bispecific)" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/prame/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/hla-a/> ;
  onco:drugs <https://onco.cc/drugs/tebentafusp/> ;
  onco:companies <https://onco.cc/companies/immunocore/> ;
  onco:trials <https://onco.cc/trials/prism-mel-301/>, <https://onco.cc/trials/nct04262466/> .